SCHEMBL2543224

SCHEMBL2543224

Cc1nc(-c2cc(CBr)no2)cs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
MAPT P10636 6/20 0.42
POLB P06746 2/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 3/20 0.38
RECQL P46063 2/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 1/20 0.38
ESR2 Q92731 1/20 0.38
TSHR P16473 1/20 0.37
PRMT6 Q96LA8 1/20 0.36
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14959671 0.85 RAB9A (0.51) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL12601877 0.82 NPC1 (0.49) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL12561742 0.81 RAB9A (0.48) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL933819 0.72
SCHEMBL569698 0.70 ECE1 (0.56) RAB9ANPC1MAPTPOLBALDH1A1
SCHEMBL29197993 0.69 TDP1 (0.55) RAB9ANPC1MAPTPOLBALDH1A1
SCHEMBL3061177 0.69 RAB9A (0.52) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL15651553 0.69 RAB9A (0.49) RAB9ANPC1MAPTPOLBMAPK1
SCHEMBL24359598 0.69 GAA (0.52) RAB9ANPC1MAPTPOLBALDH1A1
SCHEMBL125303 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937673-B1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI SA (FR) 2015-10-21 EP disclosed
US-8044208-B2 inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor); 3-(6-aminopyridin-3-yl)-2-{1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-imidazol-4-yl}propionic acid SANOFI-AVENTIS (FR) 2011-10-25 US disclosed
US-20080262028-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1937673-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007045339-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (DE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262028-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA TFPI, TFPI2, TAF1 RAB9A 2309/4885NPC1 3430/4885MAPT 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.